Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 15

1.

Acute lymphatic leukemia

A form of acute leukemia characterized by excess lympoblasts. [from HPO]

MedGen UID:
505958
Concept ID:
CN005851
Finding
2.

Chronic myelogenous leukemia

A myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. [from HPO]

MedGen UID:
505815
Concept ID:
CN004875
Finding
3.

Acute myeloid leukemia

A form of leukemia characterized by overproduction of an early myeloid cell. [from HPO]

MedGen UID:
505691
Concept ID:
CN004254
Finding
4.

Acute leukemia

MedGen UID:
505251
Concept ID:
CN002259
Finding
5.

Leukemia

A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [from HPO]

MedGen UID:
505002
Concept ID:
CN001727
Finding
6.

Abnormality of the cell cycle

An abnormality of the cell cycle. [from HPO]

MedGen UID:
451289
Concept ID:
CN116750
Finding
7.

Pre-B-cell acute lymphoblastic leukemia

MedGen UID:
428484
Concept ID:
CN004258
Finding
8.

Abnormality of B cell physiology

MedGen UID:
341411
Concept ID:
C1849242
Finding
9.

Leukemia, chronic myeloid, atypical

A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. The prognosis is usually poor. (WHO, 2001) [from NCI]

MedGen UID:
83898
Concept ID:
C0349640
Neoplastic Process
10.

Pre-B-cell acute lymphoblastic leukemia

MedGen UID:
83896
Concept ID:
C0349636
Neoplastic Process
11.

Myeloproliferative disorder

A clonal (malignant) proliferation of myeloid (erythroid, granulocytic, or megakaryocytic) cells originating from a primitive stem cell. [from NCI]

MedGen UID:
10147
Concept ID:
C0027022
Neoplastic Process
12.

AML - Acute myeloid leukemia

Familial acute myeloid leukemia (AML) with mutated CEBPA is defined as AML in which a germline CEBPA mutation is present in a family in which multiple individuals have AML. In contrast, sporadic AML with mutated CEBPA is defined as AML in which a CEBPA mutation is identified in somatic (i.e., leukemic) cells but not in germline (i.e., non-leukemic) cells. Too few persons with familial AML with mutated CEBPA have been reported to be certain about the natural history of the disease. The age of onset of familial AML with mutated CEBPA appears to be earlier than sporadic AML; disease onset has been reported in persons as young as age four years and older than age 50 years. The prognosis of individuals with familial AML with mutated CEBPA appears to be favorable (~50%-65% overall survival) compared to the ~25%-40% overall survival of those who have normal karyotype AML but no germline CEPBA mutation. Individuals with familial AML with mutated CEBPA who have been cured of their initial disease may be at greater risk of developing additional malignant clones than persons with sporadic disease. [from GeneReviews]

MedGen UID:
9730
Concept ID:
C0023467
Neoplastic Process
13.

Chronic myeloid leukemia

Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (CML), there are too many granulocytes, a type of white blood cell. Most people with CML have a gene mutation (change) called the Philadelphia chromosome. Sometimes CML does not cause any symptoms. If you have symptoms, they may include:. -Fatigue. -Weight loss. -Night sweats. -Fever. -Pain or a feeling of fullness below the ribs on the left side. Tests that examine the blood and bone marrow diagnose CML. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
7321
Concept ID:
C0023473
Neoplastic Process
14.

Myeloid leukemia

Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. [from MeSH]

MedGen UID:
7320
Concept ID:
C0023470
Neoplastic Process
15.

Acute lymphoid leukemia

Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). Genetic Heterogeneity of Acute Lymphoblastic Leukemia A susceptibility locus for acute lymphoblastic leukemia (ALL1) has been mapped to chromosome 10q21. See also ALL2 (613067), which has been mapped to chromosome 7p12.2; and ALL3 (615545), which is caused by mutation in the PAX5 gene (167414) on chromosome 9p. [from OMIM]

MedGen UID:
7317
Concept ID:
C0023449
Neoplastic Process

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...